Table 1.
Clinical characteristics of the longitudinal discovery and validation cohorts of RA patients treated with TNFi.
| Discovery | Validation | |
|---|---|---|
| Total (n=62) | Total (n=59) | |
| Female, n (%) | 53 (85.8) | 50 (84.8) |
| Age, mean (SD) | 52.9(12.9) | 53.1 (14.1) |
| DAS28_Basal, mean (SD) | 5.44 (1.18) | 5.23 (1.17) |
| DAS28_w12, mean (SD) | 4.04 (1.21) | 3.14 (1.53) |
| RF, positive (%) | 46 (88.5) | 47 (78.3) |
| ACPA positive, n (%) | 49 (79) | 43 (74.1) |
| bDMARD naive, n (%) | 14 (22.6) | 19 (31) |
| Smoking, n (%) | 16 (25.8) | 15 (25.4) |
| Treatment, n (%) | ||
| Adalimumab | 5 (8) | 7 (12) |
| Certolizumab | 10 (16) | 13 (22) |
| Etanercept | 34 (55) | 31 (52) |
| Golimumab | 12 (19.3) | 9 (15) |
| Infliximab | 1 (1.6) | 0 |